General Atlantic LLC Akero Therapeutics, Inc. Transaction History
General Atlantic LLC
- $4.28 Billion
- Q1 2024
A detailed history of General Atlantic LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, General Atlantic LLC holds 5,233,989 shares of AKRO stock, worth $123 Million. This represents 3.09% of its overall portfolio holdings.
Number of Shares
5,233,989
Previous 1,785,714
193.1%
Holding current value
$123 Million
Previous $41.7 Million
217.08%
% of portfolio
3.09%
Previous 0.6%
Shares
2 transactions
Others Institutions Holding AKRO
# of Institutions
193Shares Held
74.2MCall Options Held
429KPut Options Held
591K-
Janus Henderson Group PLC London, X06.12MShares$144 Million0.09% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$127 Million2.2% of portfolio
-
Wellington Management Group LLP Boston, MA5.21MShares$122 Million0.02% of portfolio
-
Black Rock Inc. New York, NY4.89MShares$115 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.06MShares$95.3 Million0.01% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.09B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...